Manufacturing the SARS-CoV-2 Variant with the D614G Substation

The COVID-19 pandemic is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a virus that has infected over 111 million people worldwide.

This rapid rise in infection has provided scientists with the opportunity to sequence hundreds of SARS-CoV-2 strains, allowing them to investigate the evolution of the virus and identify key mutations on an international basis rarely seen before.

The Spike (S) glycoprotein is a key viral protein responsible for COVID-19’s potency while giving the virus its crown-like appearance. This protein facilitates binding to cellular receptors such as ACE2, enabling cellular entry.

Scientists have successfully identified one key missense mutation (D614G) in this Spike protein. This was found to emerge predominantly in Europe before spreading across the globe.

The Spike protein mutation D614G encodes a mutation in the carboxy C terminal region of the S1 domain. This region of the S1 domain is directly connected to the Spike protein’s S2 domain. The D614G variant displays an increased potential for infection along with a higher rate of replication than the ancestral wild-type variant.

This mutation presents itself on the SARS-CoV-2 Spike protein (S) in cases where:

  1. The D614G is an aspartic acid to glycine substitution at amino acid position 614 in the Sars-CoV-2 S protein.

2019-nCoV spike protein S1 (D614G)

Catalog No: C19S1-G231H

Recombinant 2019-nCoV Spike protein S1 (D614G) (16-685) has been expressed in CHO cells using a C-terminal His tag.

In order to advance the fight against the COVID-19 pandemic, scientists at SignalChem have successfully manufactured a SARS-CoV-2 variant with the D614G substation.

This mutation alters the biding potential of the receptor-binding domain (RBD) of the Spike (S) protein, resulting in this being more capable of binding to the human cell receptors.

It has been hypothesized that this key mutation enhances the effectiveness of SARS-CoV-2 as well as its competitive binding and transmission capacity in both animal and human cells.

This has led to distinct challenges in terms of neutralizing antisera and the overall efficacy of vaccines currently in circulation.

The recombinant 2019-nCoV Spike protein RBD (D614G) has been expressed in CHO cells using a C terminal His tag. This protein has been subjected to rigorous QC QA tests in order to quantify its activity using functional ELISA and purity using densitometry.

The recombinant variant is ready and available for use in multiple strands of COVID-19 research, including the design and development of SARS-CoV-2 diagnostic kits and anti-viral therapeutics.

It is hoped that this protein can help expedite research against these new variants, ultimately assisting the global scientific community.

Binding of 2019-nCoV spike protein (D614G) (C19S1-G231H) to anti-2019-nCoV spike protein antibody (C19S1-61H) was determined by ELISA.

Figure 1. Binding of 2019-nCoV spike protein (D614G) (C19S1-G231H) to anti-2019-nCoV spike protein antibody (C19S1-61H) was determined by ELISA. Image Credit: SignalChem Biotech Inc.

Binding of 2019-nCoV spike protein (D614G) (C19S1-G231H) to human ACE2(19-740) protein (A51C2-G341F) was determined by ELISA.

Figure 2. Binding of 2019-nCoV spike protein (D614G) (C19S1-G231H) to human ACE2(19-740) protein (A51C2-G341F) was determined by ELISA. Image Credit: SignalChem Biotech Inc.

SignalChem: A global leader in cell signaling

SignalChem is a leader in the international cell signaling and protein engineering sectors. The company has been conducting research into the novel coronavirus since its initial outbreak, with scientists investing time and resources into better understanding the protein interaction map of SARS-CoV-2.

This research will allow the global scientific community to better engineer active recombinant SARS-CoV-2 and human proteins, and SignalChem’s goal is to provide these important pieces of the puzzle, essential for the work of researchers working on drug discovery research projects around the world.

By leveraging the power of advanced engineering technology and AI drug development software, SignalChem has already begun work on a range of projects aimed at developing expression systems of key COVID-19 related proteins.

These projects also include hot drug targets such as proteases and non-structural proteins (NSPs).

These catalytically active proteins have been described as fully functional and are suitable for use in current research projects, particularly those focussing on the development of drugs directed against coronavirus infections such as SARS-CoV-2.

About SignalChem Biotech Inc.

SignalChem is a biotech company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products.

Throughout the years, Signalchem has capitalized on its core expertise in cellular signaling, molecular biology, and protein biochemistry to generate more than 2,000 functional protein products and has established itself as the leader in the industry to produce highly active human recombinant signaling enzymes, especially protein kinases, disease-related mutant kinases, lipid kinases, epigenetic enzymes, ubiquitination-related enzymes, and neurodegenerative disease-related enzymes and proteins.

SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Mar 16, 2021 at 6:58 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    SignalChem Biotech Inc.. (2021, March 16). Manufacturing the SARS-CoV-2 Variant with the D614G Substation. News-Medical. Retrieved on April 12, 2021 from https://www.news-medical.net/whitepaper/20210309/Manufacturing-the-SARS-CoV-2-Variant-with-the-D614G-Substation.aspx.

  • MLA

    SignalChem Biotech Inc.. "Manufacturing the SARS-CoV-2 Variant with the D614G Substation". News-Medical. 12 April 2021. <https://www.news-medical.net/whitepaper/20210309/Manufacturing-the-SARS-CoV-2-Variant-with-the-D614G-Substation.aspx>.

  • Chicago

    SignalChem Biotech Inc.. "Manufacturing the SARS-CoV-2 Variant with the D614G Substation". News-Medical. https://www.news-medical.net/whitepaper/20210309/Manufacturing-the-SARS-CoV-2-Variant-with-the-D614G-Substation.aspx. (accessed April 12, 2021).

  • Harvard

    SignalChem Biotech Inc.. 2021. Manufacturing the SARS-CoV-2 Variant with the D614G Substation. News-Medical, viewed 12 April 2021, https://www.news-medical.net/whitepaper/20210309/Manufacturing-the-SARS-CoV-2-Variant-with-the-D614G-Substation.aspx.

Other White Papers by this Supplier